Abstract

HDAC inhibition is emerging as a new strategy for cancer therapy. We previously reported that Nhydroxy-3-{4-[2-(2-methyl-1H-indol-3-yl)-ethylsulfamoyl]-phenyl}-acrylamide (9) demonstrated potent histone deacetylases (HDAC) inhibition and anti-inflammatory effects. This continuous study provides detailed structureactivity relationship (SAR) of novel indol-3-ethylsulfamoylphenylacrylamides as anti-cancer agents. These compounds are endowed with potent HDAC inhibitory activity, almost 2.5 folds to 42 folds better than suberanilohydroxamic acid (SAHA). Compounds 8, 10, 11 and 17 exhibited significant inhibitory effects on various cancer cell lines with GI50 values in the range of 0.02 to 0.35 μM which are 10-50 folds better than SAHA. In-vivo nude mice model indicated the anti-angiogenic potential of these acrylamides. This study has indicated the potential of 3-{4-[2-(1-Ethyl-2-methyl-1H-indol-3-yl)-ethyl-N-tert-butoxycarbonylsulfamoyl]-phenyl}-N-hydroxy-acrylamide (11, mean GI50 = 0.04 μM) as a lead molecule for further development as anti-cancer agent.

Original languageEnglish
Pages (from-to)907-913
Number of pages7
JournalAnti-Cancer Agents in Medicinal Chemistry
Volume16
Issue number7
Publication statusPublished - Jul 1 2016

Fingerprint

Histone Deacetylases
Acrylamide
Acrylamides
Neoplasms
Nude Mice
Anti-Inflammatory Agents
Cell Line
indole
vorinostat
Therapeutics

Keywords

  • Angiogenesis
  • Cancer
  • HDAC
  • Histone
  • Indole
  • SAHA
  • Sulfonamide

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Medicine
  • Pharmacology

Cite this

Indole-3-ethylsulfamoylphenylacrylamides with potent anti-proliferative and anti-angiogenic activities. / Mehndiratta, Samir; Pan, Shiow Lin; Kumar, Sunil; Liou, Jing Ping.

In: Anti-Cancer Agents in Medicinal Chemistry, Vol. 16, No. 7, 01.07.2016, p. 907-913.

Research output: Contribution to journalArticle

@article{fea66762f1a34a839dca74dcc4b510c0,
title = "Indole-3-ethylsulfamoylphenylacrylamides with potent anti-proliferative and anti-angiogenic activities",
abstract = "HDAC inhibition is emerging as a new strategy for cancer therapy. We previously reported that Nhydroxy-3-{4-[2-(2-methyl-1H-indol-3-yl)-ethylsulfamoyl]-phenyl}-acrylamide (9) demonstrated potent histone deacetylases (HDAC) inhibition and anti-inflammatory effects. This continuous study provides detailed structureactivity relationship (SAR) of novel indol-3-ethylsulfamoylphenylacrylamides as anti-cancer agents. These compounds are endowed with potent HDAC inhibitory activity, almost 2.5 folds to 42 folds better than suberanilohydroxamic acid (SAHA). Compounds 8, 10, 11 and 17 exhibited significant inhibitory effects on various cancer cell lines with GI50 values in the range of 0.02 to 0.35 μM which are 10-50 folds better than SAHA. In-vivo nude mice model indicated the anti-angiogenic potential of these acrylamides. This study has indicated the potential of 3-{4-[2-(1-Ethyl-2-methyl-1H-indol-3-yl)-ethyl-N-tert-butoxycarbonylsulfamoyl]-phenyl}-N-hydroxy-acrylamide (11, mean GI50 = 0.04 μM) as a lead molecule for further development as anti-cancer agent.",
keywords = "Angiogenesis, Cancer, HDAC, Histone, Indole, SAHA, Sulfonamide",
author = "Samir Mehndiratta and Pan, {Shiow Lin} and Sunil Kumar and Liou, {Jing Ping}",
year = "2016",
month = "7",
day = "1",
language = "English",
volume = "16",
pages = "907--913",
journal = "Anti-Cancer Agents in Medicinal Chemistry",
issn = "1871-5206",
publisher = "Bentham Science Publishers B.V.",
number = "7",

}

TY - JOUR

T1 - Indole-3-ethylsulfamoylphenylacrylamides with potent anti-proliferative and anti-angiogenic activities

AU - Mehndiratta, Samir

AU - Pan, Shiow Lin

AU - Kumar, Sunil

AU - Liou, Jing Ping

PY - 2016/7/1

Y1 - 2016/7/1

N2 - HDAC inhibition is emerging as a new strategy for cancer therapy. We previously reported that Nhydroxy-3-{4-[2-(2-methyl-1H-indol-3-yl)-ethylsulfamoyl]-phenyl}-acrylamide (9) demonstrated potent histone deacetylases (HDAC) inhibition and anti-inflammatory effects. This continuous study provides detailed structureactivity relationship (SAR) of novel indol-3-ethylsulfamoylphenylacrylamides as anti-cancer agents. These compounds are endowed with potent HDAC inhibitory activity, almost 2.5 folds to 42 folds better than suberanilohydroxamic acid (SAHA). Compounds 8, 10, 11 and 17 exhibited significant inhibitory effects on various cancer cell lines with GI50 values in the range of 0.02 to 0.35 μM which are 10-50 folds better than SAHA. In-vivo nude mice model indicated the anti-angiogenic potential of these acrylamides. This study has indicated the potential of 3-{4-[2-(1-Ethyl-2-methyl-1H-indol-3-yl)-ethyl-N-tert-butoxycarbonylsulfamoyl]-phenyl}-N-hydroxy-acrylamide (11, mean GI50 = 0.04 μM) as a lead molecule for further development as anti-cancer agent.

AB - HDAC inhibition is emerging as a new strategy for cancer therapy. We previously reported that Nhydroxy-3-{4-[2-(2-methyl-1H-indol-3-yl)-ethylsulfamoyl]-phenyl}-acrylamide (9) demonstrated potent histone deacetylases (HDAC) inhibition and anti-inflammatory effects. This continuous study provides detailed structureactivity relationship (SAR) of novel indol-3-ethylsulfamoylphenylacrylamides as anti-cancer agents. These compounds are endowed with potent HDAC inhibitory activity, almost 2.5 folds to 42 folds better than suberanilohydroxamic acid (SAHA). Compounds 8, 10, 11 and 17 exhibited significant inhibitory effects on various cancer cell lines with GI50 values in the range of 0.02 to 0.35 μM which are 10-50 folds better than SAHA. In-vivo nude mice model indicated the anti-angiogenic potential of these acrylamides. This study has indicated the potential of 3-{4-[2-(1-Ethyl-2-methyl-1H-indol-3-yl)-ethyl-N-tert-butoxycarbonylsulfamoyl]-phenyl}-N-hydroxy-acrylamide (11, mean GI50 = 0.04 μM) as a lead molecule for further development as anti-cancer agent.

KW - Angiogenesis

KW - Cancer

KW - HDAC

KW - Histone

KW - Indole

KW - SAHA

KW - Sulfonamide

UR - http://www.scopus.com/inward/record.url?scp=84973626733&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84973626733&partnerID=8YFLogxK

M3 - Article

C2 - 26459769

AN - SCOPUS:84973626733

VL - 16

SP - 907

EP - 913

JO - Anti-Cancer Agents in Medicinal Chemistry

JF - Anti-Cancer Agents in Medicinal Chemistry

SN - 1871-5206

IS - 7

ER -